文献速递核素与放射性配体治疗骨显像与常规 SPECT

[177Lu]Lu-EDTMP——一种骨痛姑息治疗药物:在骨转移患者中的药代动力学、生物分布、安全性特征及临床评价

[177Lu]Lu-EDTMP -a bone pain palliating agent: pharmacokinetics, biodistribution, safety profile and clinical evaluation in osseous metastatic patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-02

本I/II期研究在27例乳腺癌和前列腺癌骨转移患者中评估[177Lu]Lu-EDTMP,17例分析药代动力学与生物分布,18例接受低活度(1.3 GBq)或高活度(2.6 GBq)治疗。结果显示血液清除快、骨摄取超过70%、转移灶选择性摄取,两组均有显著疼痛缓解,高活度组起效更快、持续更久,未发生III/IV级骨髓毒性或主要肾/肝事件。

要点

  • 27例骨转移患者纳入研究,药代动力学与生物分布分析17例,疗效与安全性评价18例。
  • 24小时血液残留活性可忽略,尿排泄超过给药活度的30%,骨摄取逐步增至超过70%。
  • 低活度(1.3 GBq)与高活度(2.6 GBq)组均显著缓解疼痛,高活度组起效更快、持续更久。

核心结论

  • [177Lu]Lu-EDTMP是一种安全有效的骨痛姑息治疗药物,具有良好的药代动力学、靶向骨骼摄取和极低毒性。
  • 研究结果支持其作为骨转移患者疼痛姑息治疗的替代放射性药物。

研究设计与样本

  • I/II期研究,纳入27例乳腺癌和前列腺癌骨转移患者。
  • 药代动力学与生物分布在17例患者中通过全身伽马照相机显像和多时间点定量分析。
  • 临床疗效与安全性在18例接受低活度(1.3 GBq)或高活度(2.6 GBq)治疗的患者中评估,安全性通过12周血液学和生化监测确定。

主要发现

  • [177Lu]Lu-EDTMP血液清除快,24小时残留活性可忽略,24小时尿排泄超过给药活度的30%。
  • 骨摄取逐步增加至超过70%,闪烁显像显示转移灶选择性摄取,病灶/骨与病灶/软组织比值改善。
  • 低活度(1.3 GBq)与高活度(2.6 GBq)组均显示显著疼痛缓解,高活度组起效更快、持续时间更长,并减少阿片类/非甾体抗炎药使用。
  • 未发生III/IV级骨髓毒性或主要肾/肝事件。

关键数值与推荐

  • 疼痛缓解采用视觉模拟评分、镇痛药使用(频率和类型)、活动能力评分和Karnofsky体能状态评估。
  • 低活度为1.3 GBq,高活度为2.6 GBq。

临床怎么用

  • 原文结论支持[177Lu]Lu-EDTMP作为骨转移患者疼痛姑息治疗的潜在替代放射性药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: [177Lu]Lu-EDTMP has emerged as a promising radiopharmaceutical for the palliation of pain caused by osseous metastases. This phase I/II study comprehensively evaluate the pharmacokinetics, biodistribution, clinical efficacy, and safety profile of [177Lu]Lu-EDTMP, in patients with skeletal metastases from breast and prostate cancer. METHODS: A total of 27 patients with skeletal metastases were included in the study. Pharmacokinetics and biodistribution were analyzed in 17 patients through whole-body gamma camera imaging and quantification at multiple time points. Clinical efficacy and safety were evaluated in 18 patients receiving either low (1.3 GBq) or high (2.6 GBq) administered activity. Pain palliation was assessed using visual analog scale scores, analgesic usage (frequency and type), mobility scores, and Karnofsky performance status. The safety profile was determined through hematological and biochemical monitoring over 12 weeks. RESULTS: [177Lu]Lu-EDTMP demonstrated rapid blood clearance, with negligible residual activity at 24 h. Urinary excretion accounted for over 30% of administered activity at 24 h. Bone uptake increased progressively to over 70%. Scintigraphy revealed selective uptake in metastases, improving lesion-to-bone and lesion-to-soft tissue ratios. Both low (1.3 GBq) and high (2.6 GBq) activity groups showed significant pain relief, with faster, longer-lasting effects in the high-dose group, reducing opioid/NSAID use. No Grade III/IV myelotoxicity or major renal/hepatic events occurred. CONCLUSION: [177Lu]Lu-EDTMP is a safe and effective bone pain palliation agent, with favorable pharmacokinetics, targeted skeletal uptake, and minimal toxicity. These findings support its potential use as an alternative radiopharmaceutical for pain palliation in patients with skeletal metastases. CLINICAL TRIAL NUMBER: Not applicable.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Saeed S, Paez D, Estrada Lobato E, et al. [177Lu]Lu-EDTMP -a bone pain palliating agent: pharmacokinetics, biodistribution, safety profile and clinical evaluation in osseous metastatic patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 40172696. doi:10.1007/s00259-025-07218-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。